ChinaDrugStatus

Eliglustat tartrate

酒石酸艾格司他
Brand: Cerdelga / 凯奇安·Rare Disease / Metabolic·Last verified 2026-11-20

Oral substrate reduction therapy for Gaucher disease type 1 whose 2026 NRDL entry adds pediatric coverage (age ≥6, ≥15 kg) and adjusts payment standard from ¥381.00 to ¥361.95.

China Approval (NMPA)

Pending Verification

Reimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.

Verify directly on NMPA Portal ↗

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #41 · Class B
Agreement Period
2027-01-01 to 2027-12-31
Payment Standard
361.95元(84mg/粒(按C23H36N2O4计))
2026 Payment Scope
Expanded to cover both adult GD1 patients and pediatric GD1 patients (age ≥6 years, weight ≥15 kg, stable on ERT) who are CYP2D6 PMs, IMs, or EMs; published standard adjusted from ¥381.00 to ¥361.95 per 84mg capsule.
限:1.经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者;2.6岁及以上,体重15公斤及以上,酶替代治疗(ERT)稳定,以及经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)儿童患者的治疗。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #38NHSA · PDF p.129

Restricted to adult Gaucher disease type 1 (GD1) patients who are CYP2D6 poor, intermediate, or extensive metabolizers.

限经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者。

2026 NRDL · #41NHSA · PDF p.119

Expanded to cover both adult GD1 patients and pediatric GD1 patients (age ≥6 years, weight ≥15 kg, stable on ERT) who are CYP2D6 PMs, IMs, or EMs; published standard adjusted from ¥381.00 to ¥361.95 per 84mg capsule.

限:1.经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)成年患者;2.6岁及以上,体重15公斤及以上,酶替代治疗(ERT)稳定,以及经CYP2D6基因型检测为弱代谢型(PMs)、中间代谢型(IMs)或快代谢型(EMs)的Ⅰ型戈谢病(GD1)儿童患者的治疗。

Approved Products, Dosage Forms & Approval Numbers

0 verified NMPA records
Individual NMPA approval numbers (国药准字) and dosage strength rows have not yet been manually backfilled for this drug in our launch sample. Check the NMPA Drug Database Portal ↗ or request priority backfill.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule).

    Chinese original: 支付范围新增6岁及以上且体重≥15公斤、ERT稳定的Ⅰ型戈谢病儿童患者,支付标准同步由381.00元调整为361.95元(84mg/粒)。

    NHSA · PDF p.119Verified 2026-11-20

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

酒石酸艾格司他胶囊dosage name(NHSA)
Cerdelgabrand en(WHO)
凯奇安brand zh(NMPA)

Primary Sources for This Record